Ongoing Trial: AGT-182 Phase 1 Trial in Hunter Syndrome

The purpose of this Phase 1 clinical trial is to test the safety and determine a well-tolerated dose of the investigational treatment AGT-182 for male patients (age 18 years and older) with Hunter syndrome or mucopolysaccharidosis type II (MPS II).

Patients in the trial will receive weekly infusions of AGT-182 at assigned doses that range from 1 mg/kg for the first dose group of patients enrolled and increase to 3.0 mg/kg. Additional higher dose levels may be added. AGT-182 will be administered intravenously over a 3-hour period for eight weeks.

More information about the trial is available on, or using the identifier number NCT02262338.

Breaking Barriers Trial


Add this Badge

Click here to add this badge, which links to the Breaking Barriers Hunter Syndrome clinical trial website, to your website or blog.

Breaking Barriers Hunter Syndrome Clinical Trial

ArmaGen’s CEO and the company’s VP, Clinical Affairs discuss the AGT-182 Phase 1 clinical trial for Hunter syndrome

First human clinical trial for Hunter syndrome underway at Emory

Video by Emory University featuring first patient dosed in AGT-182 trial. Comments and opinions are not necessarily endorsed by ArmaGen.

Ongoing Trial: AGT-181 Phase 1 Trial in MPS I

ArmaGen is recruiting for a Phase 1 clinical trial in the second quarter of 2015 to assess safety and determine a well-tolerated dose of AGT-181 in adult patients with Hurler-Scheie and Scheie, which are less severe forms of MPS I. ArmaGen plans to enroll nine patients 18 years and older into the study. These patients will be treated for a total of eight weeks, with all enrolled patients receiving AGT-181.

Further details on the trial can be found on using the identifier number NCT02371226.

Pending the results of the Phase 1 trial, ArmaGen plans to conduct subsequent studies in a broader population of patients with MPS I, including those with Hurler syndrome.